ACARIX — Acarix ABHealthcare · Medical DevicesOMXSTO
SEK 307.5M
Mkt Cap
SEK 289.3M
Ent. Value
SEK 0.26
52W SEK 0 – SEK 0
SEK 307.5M
Mkt Cap
SEK 289.3M
Ent. Value
N/M
P/E TTM
—
PEG
—
P/FCF
8.1×
P/Book
41.8×
P/Sales
—
EV/EBITDA
—
EV/EBIT
—
EV/FCF
39.3×
EV/Sales
-15.6%
Earn Yld
-12.3%
FCF Yld
—
Div Yld
SEK 0.26
·
All values in Swedish Krona (SEK)
SEK
FY2025
FY2024
FY2023
FY2022
Revenue
7.36M
6.20M
6.24M
5.82M
YoY Growth
+18.7%
-0.6%
+7.2%
—
Gross Profit
6.24M
5.59M
5.30M
4.62M
Gross Margin
84.7%
90.2%
84.9%
79.4%
R&D
14.76M
25.39M
28.52M
27.76M
SG&A
39.49M
46.58M
54.33M
53.34M
EBIT
(48.01M)
(66.37M)
(77.55M)
(76.47M)
EBIT Margin
-652.2%
-1070.2%
-1242.6%
-1313.6%
D&A
3.48M
3.29M
3.09M
3.04M
EBITDA
(44.61M)
(62.78M)
(74.62M)
(73.78M)
EBITDA Margin
-606.1%
-1012.3%
-1195.6%
-1267.3%
Net Income
(48.09M)
(66.19M)
(77.84M)
(76.98M)
Net Margin
-653.3%
-1067.2%
-1247.2%
-1322.3%
EPS (diluted)
-SEK 0.04
-SEK 0.07
-SEK 0.16
-SEK 0.31
Shares (dil., M)
1127
921
475
262
Company Brief
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
